Endogenous fibrinolysis inhibitors in acute coronary syndrome

Area of Science:

• Cardiology
• Hematology
• Thrombosis Research

Background:

• Acute coronary syndrome (ACS) patients have significant residual ischemic risk despite current invasive and antithrombotic therapies.
• Early revascularization and stenting of non-hemodynamically significant lesions have not consistently reduced major adverse cardiovascular events.
• Impaired fibrinolysis is increasingly recognized as a critical independent risk factor for mortality and adverse outcomes in ACS.

Purpose of the Study:

• To review the association between impaired fibrinolysis and adverse cardiovascular outcomes in ACS.
• To explore the role of endogenous fibrinolysis inhibitors in ACS.
• To summarize experimental evidence on modulating fibrinolysis using profibrinolytic agents targeting these inhibitors.

Main Methods:

• Literature review of studies investigating fibrinolysis, endogenous inhibitors, and cardiovascular outcomes in ACS.
• Analysis of data linking impaired fibrinolysis to major adverse cardiovascular events.
• Summary of experimental research on therapeutic interventions targeting fibrinolytic pathways.

Main Results:

• Impaired fibrinolysis is strongly associated with increased cardiovascular mortality and adverse events in ACS patients.
• Endogenous fibrinolysis inhibitors are implicated in the pathophysiology of impaired fibrinolysis in ACS.
• Experimental data suggests potential for profibrinolytic agents to improve the fibrinolytic state.

Conclusions:

• Impaired fibrinolysis represents a significant therapeutic target in managing ACS.
• Targeting endogenous fibrinolysis inhibitors with profibrinolytic agents may offer novel strategies to reduce residual cardiovascular risk in ACS patients.